Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases - PubMed (original) (raw)

Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases

C Peña et al. Antimicrob Agents Chemother. 1998 Jan.

Abstract

An outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KP) was detected from May 1993 to June 1995. A total of 145 patients, particularly patients in intensive care units (ICUs) (107 patients [72%]), were colonized or infected. Infection developed in 92 (63%) patients, and primary bacteremia caused by ESBL-KP was the most frequent infection (40 of 92 patients [43%]). A single clone of ESBL-KP was identified by pulsed-field gel electrophoresis analysis throughout the whole period, and no molecular epidemiological relationship could be found between the epidemic strain and non-ESBL-KP isolates. To determine risk factors for ESBL-KP infection weekly rectal swabs were obtained in three serial incidence surveys (470 patients); the probabilities of carriage of ESBL-KP in the digestive tract were 33% (October and November 1993), 40% (May and June 1994), and 0% (October and November 1995) at 10 days of ICU admission. A logistic regression model identified prior carriage of ESBL-KP in the digestive tract (odds ratio, 3.4; 95% confidence interval 1.1 to 10.4) as an independent variable associated with ESBL-KP infection. A statistically significant correlation was observed between the restricted use of oxyimino-beta-lactams (189 defined daily doses [DDD]/ 1,000 patient-days to 24 DDD/1,000 patient-days) and the trends of ESBL-KP infection (r = 0.7; P = 0.03).

PubMed Disclaimer

Figures

FIG. 1

Numbers of patients colonized or infected with K. pneumoniae over the course of the study period.

FIG. 2

ESBL-KP and non-ESBL-KP incidence rates in ICUs after the implementation of the restricted use of oxyimino-β-lactams in ICUs.

FIG. 3

Probability of remaining free of digestive tract colonization with ESBL-KP. Line with slashes, first period; line with squares, second period; solid line, third period.

FIG. 4

PFGE of total DNA from K. pneumoniae isolates cut with _Xba_I. (A) ESBL-KP isolates. Lane 1, PFGE marker (New England BioLabs); lanes 2 and 3, isolates from the blood of non-ICU patients; lanes 4 to 6 and 10, isolates from the blood of ICU patients; lanes 7 and 8, 11 and 12, and 13 and 14, isolates from the blood and feces of three patients, respectively; lane 9, blood isolate with a susceptibility pattern different from those of the other isolates. (B) Non-ESBL-KP isolates. Lane 1, PFGE marker (New England BioLabs); lanes 2 to 8, 10, 11, 13, and 14, isolates from the blood of 11 patients, respectively; lanes 9 and 12, non-ESBL-KP strains isolated from the blood of the same patient during two different episodes of bacteremia, respectively.

Cited by

Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study.
Lueangarun S, Leelarasamee A. Lueangarun S, et al. Interdiscip Perspect Infect Dis. 2012;2012:765205. doi: 10.1155/2012/765205. Epub 2012 Aug 2. Interdiscip Perspect Infect Dis. 2012. PMID: 22919379 Free PMC article.
Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.
Mattner F, Bange FC, Meyer E, Seifert H, Wichelhaus TA, Chaberny IF. Mattner F, et al. Dtsch Arztebl Int. 2012 Jan;109(3):39-45. doi: 10.3238/arztebl.2012.0039. Epub 2012 Jan 20. Dtsch Arztebl Int. 2012. PMID: 22334820 Free PMC article. Review.
Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods.
Castillo García FJ, Seral García C, Pardos De la Gandara M, Millán Lou MI, Pitart Ferré C. Castillo García FJ, et al. Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):77-8. doi: 10.1007/s10096-006-0242-8. Eur J Clin Microbiol Infect Dis. 2007. PMID: 17180346 No abstract available.
A Novel Role for the Klebsiella pneumoniae Sap (Sensitivity to Antimicrobial Peptides) Transporter in Intestinal Cell Interactions, Innate Immune Responses, Liver Abscess, and Virulence.
Hsu CR, Chang IW, Hsieh PF, Lin TL, Liu PY, Huang CH, Li KT, Wang JT. Hsu CR, et al. J Infect Dis. 2019 Apr 8;219(8):1294-1306. doi: 10.1093/infdis/jiy615. J Infect Dis. 2019. PMID: 30476200 Free PMC article.
A Novel Peptide as a Specific and Selective Probe for Klebsiella pneumoniae Detection.
Kim H, Jang JH, Jung IY, Cho JH. Kim H, et al. Biosensors (Basel). 2022 Mar 1;12(3):153. doi: 10.3390/bios12030153. Biosensors (Basel). 2022. PMID: 35323423 Free PMC article.

References

1. Arlet G, Sanson-Le Pors M J, Rouveau M, Fournier G, Marie O, Schlemmer B, Philippon A. Outbreak of nosocomial infections due to Klebsiella pneumoniae producing SHV-4 β-lactamase. Eur J Clin Microbiol Infect Dis. 1990;9:797–803. - PubMed
1. Arlet G, Rouveau M, Casin I, Buvet P J M, Lagrande P H, Philippon A. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. J Clin Microbiol. 1994;32:2553–2558. - PMC - PubMed
1. Barza M, Giuliano M, Jacobos N V, Gorbach S L. Effect of broad-spectrum parenteral antibiotics on “colonization resistance” of intestinal microflora of humans. Antimicrob Agents Chemother. 1987;31:723–727. - PMC - PubMed
1. Bauerfeind A, Rosenthal E, Eberlein E, Holley M, Schweighart S. Spread of Klebsiella pneumoniae producing SHV-5 β-lactamase among hospitalized patients. Infection. 1993;21:18–22. - PubMed
1. Boyce J M. Treatment and control of colonization in the prevention of nosocomial infections. Infect Control Hosp Epidemiol. 1996;17:256–261. - PubMed

Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases - PubMed (original) (raw)